A Multicenter, Open-label, Single-arm, Phase 4 Study to Evaluate the Efficacy and Safety of Filgotinib in Korean Patients With Rheumatoid Arthritis
Latest Information Update: 15 May 2026
At a glance
- Drugs Filgotinib (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Eisai Korea
Most Recent Events
- 11 May 2026 Status changed from active, no longer recruiting to completed.
- 03 Sep 2025 Status changed from recruiting to active, no longer recruiting.
- 09 Jul 2025 Planned End Date changed from 27 Oct 2025 to 19 Mar 2026.